Atom Therapeutics is a clinical stage biotechnology company founded in 2012. Atom is developing best-in-class orally delivered small molecule drugs for treatment of inflammatoryand metabolic diseases, such as chronic gout, for which there are no effective treatments.
Atom’s lead therapy, ABP-671, for chronic gout, is more potent and significantly less toxic than existing drugs, and is poised to enter global Phase 3 trials in 2022. Another compound, ABP-6016, has demonstrated safety and efficacy in preclinical trials for NASH, which is projected to become the most common cause of liver disease.
To learn more about Atom Therapeutics visit our website.
Company Details
- Employees
- 3
- Founded
- -
- Address
- Suzhou, Jiangsu, Cn
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://atombp.com
- HQ
- Suzhou, Jiangsu
Atom Therapeutics Questions
Atom Therapeutics's website is http://atombp.com
Atom Therapeutics's LinkedIn profile is https://cn.linkedin.com/company/atom-therapeutics
Atom Therapeutics has
3 employees.
View email and phone details for 3
employees at Atom Therapeutics.
Atom Therapeutics's industry is
Pharmaceutical Manufacturing
Atom Therapeutics's top competitors are
China Medical System Holdings Ltd,
Eupraxia Pharmaceuticals Inc.,
Apitbio Inc.,
Senti Biosciences,
Gossamer Bio,
Hightide Therapeutics,
Samjin Pharmaceutical Co Ltd,
Pulmokine, Inc.,
Olema Oncology,
Intercept Pharmaceuticals.
Atom Therapeutics's categories are Pharmaceutical Manufacturing
Atom Therapeutics's founding year is 2012
